Hims & Hers Health, Inc. (HIMS)

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 33.94 (as of 2026-06-26)

The panel divides along a single fault line: is Hims & Hers a durable consumer-health platform, or a regulatory-arbitrage machine whose margins compress each time a loophole closes? After the FDA and Novo Nordisk forced an exit from high-margin compounded semaglutide, gross margin fell from 82% to 65% and the company is now a branded-Wegovy distribution channel — five of six frameworks place fair value below the ~USD 34 price, and only the growth archetype is a buyer here. The synthesized read lands on WAIT rather than a directional call because a dated catalyst (Q2 2026 earnings in August) and a clear lower-value cluster (roughly USD 13–22) sit between the panel and a verdict.

Key levels

	Level
Resistance R3 / R2 / R1	USD n/a / n/a / n/a
Current price	USD 33.94
Support S1 / S2 / S3	USD n/a / n/a / n/a
Analyst consensus target	USD 21 – 37 – 85

The panel did not establish current technical levels — the chart read needs live verification after a ~25% move in June — so key support and key resistance are marked n/a here. The analyst consensus target spans roughly USD 21 to 85, averaging near USD 37, with the panel's own fair-value estimates clustering well below the current price.

What legendary investors think

We ran Hims & Hers Health past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is Hims & Hers a durable consumer-health platform, or a regulatory-arbitrage machine whose margins compress each time a loophole closes? The Disruptive-Innovation Seeker's USD 85 needs the former; the Forensic Skeptic's USD 13 and the Moat Compounder's USD 9–12 assume the latter.

The numbers

Metric	Value
Price / Market cap	USD 33.94 / ~7.6B
P/E (TTM / fwd)	n/a (loss-making TTM) / ~42x
ROE	-2.66%
Operating margin	~ -12.9% (Q1 2026)
Dividend yield	0% (no dividend)
Debt / equity	2.54x (rising post-Eucalyptus)
Free cash flow	USD 53M (Q1 2026)

Figures as of Q1 2026 / June 2026; sourced from Hims & Hers IR/SEC filings, StockAnalysis, Macrotrends, and analyst data (MarketBeat). Q1 2026 net loss of ~USD 92M was driven largely by ~USD 33.5M of restructuring plus non-cash items; underlying quarterly free cash flow stayed positive.

The bottom line

The tension is structural, not cosmetic. Hims & Hers built explosive 2024–2025 growth on compounded semaglutide, a high-margin regulatory window that the FDA and Novo Nordisk closed; the rebuilt model — distributing branded Wegovy and Ozempic through a Novo partnership — is lower-margin (gross margin 82% → 65%) and runs at a partner's pricing discretion, even as the company layers on USD 1.15B of Eucalyptus acquisition obligations with debt/equity at 2.54x. Against that, the platform itself is real: 2.58M subscribers, a trusted brand, 125,000 branded-Wegovy shipments in six weeks, and raised FY2026 guidance of USD 2.8–3.0B. What would tip the panel constructive is the August quarter showing gross margin recovering toward 70% and subscribers holding above 2.58M — proof the new economics work — or a price near the USD 13–22 zone where even the skeptics see value; what would reopen the bear case is a Q2 revenue miss below the ~USD 680M floor, subscribers falling quarter-on-quarter as patients face branded-drug pricing, or margins staying below 65%. With a dated catalyst weeks away (Q2 earnings, plus an FDA peptide advisory meeting on July 23–24) and most fair-value estimates well under the market price, the growth-versus-quality question stays unresolved.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 34.38 (as of 2026-07-11)

Hims & Hers is the panel's textbook "good disruptor, wrong price, resolved-but-changed story" call — and the reason it lands on WAIT rather than a directional verdict is that the outcome is genuinely bimodal. The engine that drove 59% revenue growth in FY25 was compounded semaglutide, and it is gone: the FDA ended the shortage that made compounding legal, Novo Nordisk sued over patents, and Hims was forced into a March 2026 settlement that turned it into a branded Wegovy distributor — lower margin, and dependent on the very supplier that just sued it. The damage is on the tape: Q1 revenue grew only 4% year over year, gross margin fell from 73% to 65%, adjusted EBITDA halved, and the company swung to a $92M net loss. Four lenses (the Moat Compounder, GARP Operator, Intrinsic-Value Modeler, and Forensic Skeptic) are bearish with fair values clustering $18-33 — mostly below the current $34 — and only the Disruptive-Innovation Seeker is a buyer, seeing a pharmacy/primary-care platform, not a weight-loss fad. But three things stop this being a SELL: the durable core (dermatology, sexual health, mental health, hair — 2.6M subscribers, +9%) is intact and free-cash-flow positive, the Novo settlement removed the existential lawsuit risk, and short interest near 42% of float makes the stock a violent two-way instrument where the downside isn't cleanly dominant. With a dated catalyst (Q2 earnings in August) and a wide fair-value cluster straddling the price, the synthesis is WAIT.

Key levels

Key resistance starts at ~$40 (the 2026 recovery high near $37.57 and round-number supply), then ~$50, up to the ~$60-65 shelf from the pre-collapse structure — a move above ~$40 on volume, with a reclaim of the declining 200-week average, is what the technical lens treats as confirmation the basing is real. Key support sits at ~$31 (the recent shelf), then ~$28 (roughly the S&P Capital hold-rating fair value of $28.35), with a deeper structural level near ~$22 and the capitulation zone toward $19-21. The analyst consensus target spans USD 21 to 40, averaging near USD 29 — below the current price, an unusual configuration where the Street's average fair value sits under where the stock trades, reflecting how far sentiment diverges on a battleground name.

What legendary investors think

We ran Hims & Hers past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is Hims & Hers a durable, multi-category consumer-health platform whose Q1 loss was a necessary re-basing onto branded revenue — with the existential lawsuit now resolved — or a regulatory-arbitrage machine that just lost its highest-margin product, priced at a level most frameworks call too rich, where the honest move is to wait for the branded economics to prove out?

The numbers

Metric	Value
Price / Market cap	USD 34.38 / ~8.5B
Revenue growth	+4% YoY (Q1'26; down from 59% in FY25)
Subscribers	2.6M (+9% YoY); revenue/sub $85 → $80
Gross margin	65% (from 73%)
Adjusted EBITDA	USD 44M (from $91M; ~7% margin)
Net income (Q1)	−USD 92M (vs +$49.5M prior year); EPS −$0.40 vs +$0.01 est
Free cash flow	+USD 53M (positive)
FY26 guide	Revenue USD 2.8–3.0B; adj. EBITDA $275–350M (wide range = low visibility)
Valuation	Fwd EV/EBITDA ~28x; EV/sales ~3x; fwd P/E ~34x
Short interest	42.8% of float ($1.39B)

Figures as of Q1 2026 / July 11, 2026; sourced from Hims & Hers IR/SEC filings, TipRanks, S&P Capital IQ, MarketBeat, StockAnalysis. GLP-1 timeline: the FDA ended the semaglutide shortage (making compounding no longer permitted), Novo Nordisk sued over patents (the stock fell ~78% toward $13.74), then a March 9, 2026 settlement gave Hims a branded-Wegovy distribution deal (125k+ shipments in six weeks). Competitive/regulatory pressure continued: Lilly's oral orforglipron was approved in April, and on April 30 the FDA proposed excluding semaglutide/tirzepatide from 503B compounding. A JPMorgan $400M receivables facility drove the stock to a 2026 high of ~$37.57. Management targets ~$6.5B revenue / $1.3B EBITDA by 2030; BofA (Neutral, $37) flags that $39-intro Wegovy subscribers may churn at the $149/mo step-up. Next print: Q2 2026 earnings, August.

The bottom line

Hims & Hers is the panel's most balanced WAIT — a genuine disruptor whose highest-margin engine was legislated away, leaving a business the panel can't yet price with confidence. The bear case is concrete and, on the numbers, dominant: compounded semaglutide is dead, not fading; growth collapsed from 59% to 4%; gross margin fell to 65%; the company swung to a $92M loss; and the forced pivot to branded Wegovy trades a high-margin proprietary product for low-margin distribution of a supplier's drug — which is why the value, GARP, intrinsic-value, and forensic lenses all sit at fair values between roughly $18 and $33, mostly below the $34 price, with the CEO a persistent net seller and short interest near 42%. But three things keep this from being a SELL. First, the durable core — dermatology, sexual health, mental health, and hair, at 2.6M subscribers and free-cash-flow positive — is intact and roughly equals the whole company's current value, meaning the market is paying little for the GLP-1 optionality. Second, the Novo settlement removed the existential lawsuit that took the stock to $13; the risk that remains is margin and dependency, not survival. Third, the outcome is genuinely bimodal — fair values span $19 to $42 — and with 42% of the float short, the two-way risk is violent enough that a directional bet in either direction is really a bet on the next headline. What would resolve it is the August Q2 print: evidence that branded economics can hold margins and that the durable core is re-accelerating would validate the disruptive lens; another quarter of margin compression and single-digit growth would confirm the skeptics. Until the branded pivot proves out over two or three quarters, the honest read on a modestly rich, structurally changed, heavily contested business is to wait.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 32.84 (as of 2026-07-18)

What changed since 2026-07-11:

• Price: USD 34.38 → 32.84 (−4.5%) — an intraweek rip to a $37.80 high on short-covering, giving back more than half the move to close lower for the week.
• Panel: 1 of 6 → 0 of 6 now Bullish (The Disruptive-Innovation Seeker moved from Bullish to Neutral) — the panel's lone bull steps back to the sideline, unwilling to underwrite the platform case until the branded-distributor numbers prove out.
• Trigger: The August Q2 earnings print — the single dated catalyst every lens is waiting on to resolve the bimodal fair-value spread, not this week's short-covering noise.
• Verdict: WAIT (unchanged)

Nothing about the underlying business changed this week — the story stays genuinely bimodal, with fair values spanning roughly $18-22 on the bearish end to ~$42 on the bullish end, and no lens treats the August print as pre-empted by this week's short-covering noise. The lone escalation is the Forensic Skeptic, who moves from Neutral-leaning to outright Bearish: at ~32-33x forward earnings and an $8.1B cap for a company that just posted a $92M net loss, with the analyst consensus midpoint ($29) sitting below today's price, the crowd's own price targets don't support the crowd's own price — though even that lens says it will wait for the print rather than call for an exit today.

Key levels

Key resistance sits near $38-40 (this week's failed rally to $37.80 plus round-number supply), then $50, up to the $60 shelf from the pre-collapse structure — a reclaim of $38-40 on real volume is what the technical lens treats as evidence the rally is more than short-covering. Key support sits at $31 (this week's shelf, now converged with the Supertrend cushion), then $28 (roughly the historical accumulation zone from the prior fair-value work), with a deeper zone near $22 marking the top of the $18-22 bear-case range. The analyst consensus target spans USD 21 to 40, averaging near USD 29 — still below the current price, the same unusual configuration flagged last week.

What legendary investors think

We ran Hims & Hers past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the August Q2 print show the branded-distributor economics stabilizing on top of a durable, FCF-positive subscription core — validating the optimistic reading — or does it confirm a structurally lower-margin business still trading above what its own analyst consensus target implies?

The numbers

Metric	Value
Price / Market cap	USD 32.84 / ~$8.1B
P/E (TTM / fwd)	n/a (net loss, TTM) / ~32-33x (fwd)
ROE	n/a (not reported)
Revenue growth	+4% YoY (Q1'26; down from +59% in FY25)
Gross margin	65% (from 73%)
Net income (Q1)	−USD 92M
Free cash flow	+USD 53M (positive)
Subscribers	2.6M
Short interest	~42.8% of float

Figures as of Q1 2026 / July 18, 2026, cross-referenced against the July 11, 2026 analysis; the underlying fundamentals (revenue growth, gross margin, net loss, FCF, subscriber count) are unchanged week over week — only price and short-interest-driven volatility moved. Next print: Q2 2026 earnings, August.

The bottom line

What would move this from WAIT: a close below the $31 shelf on volume would confirm the bear case's read that this week's rally was purely short-covering positioning, not new information, while a reclaim of $38-40 on real volume would signal the market is starting to price in the branded-distributor economics holding up rather than just short-covering. The August Q2 print is the harder catalyst — evidence that gross margin stabilizes near the current 65% level would support the Neutral majority tipping Bullish; another leg of margin compression or a fresh net-loss surprise would tip it toward the Forensic Skeptic's Bearish read instead. A convergence of the $29 analyst consensus midpoint toward or above the current price post-earnings is also worth tracking, given every lens already flags that gap as unresolved. Until the print, 42.8% short interest keeps two-way volatility elevated without adding new information.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: USD 28.09 (as of 2026-07-25)

What changed since 2026-07-18:

• Price: USD 32.84 → 28.09 (−14.5%) — a decisive close below the $31 shelf both The Forensic Skeptic and The Macro Opportunist flagged last week as the line between short-covering noise and a confirmed bear read. The break came on a volume-confirmed reversal week (87.4M shares), not thin trading.
• Panel: 1 of 6 → 2 of 6 now Bearish (The Macro Opportunist moves from Neutral to Bearish); The Forensic Skeptic escalates from Medium to High conviction. Still 0 of 6 Bullish — the other four lenses (Moat Compounder, GARP Operator, Disruptive-Innovation Seeker, Intrinsic-Value Modeler) hold Neutral.
• New catalyst, not yet resolved: the FDA Pharmacy Compounding Advisory Committee voted 8-6 (and 7-5-2 on one peptide) to add four compounded peptides to the 503A Bulks List, going against FDA staff's own prior position, which had opposed all seven — a genuine incremental positive for the compounding-pharmacy lane, but non-binding, with formal rulemaking up to a year out.
• New risk, not thesis-breaking on its own: the CFO sold ~$229K of shares days before that FDA vote, and the company disclosed the Chief Accounting Officer's resignation (effective October, CFO stepping in on an interim basis) — flagged by the Forensic Skeptic as a governance red flag landing right before the August print.
• Offsetting positive: management raised Q2 2026 revenue guidance to $680-700M (+25-28% YoY) and lifted the FY2026 outlook to $2.8-3.0B revenue at roughly 11% adjusted EBITDA margin — the first sign since Q1's margin collapse that the post-Novo branded-distributor economics may be stabilizing rather than deteriorating further.
• Verdict: WAIT (unchanged)

Nothing this week resolves the bimodal story the panel has been sitting on since before the last print — it sharpens it. The stock did exactly what the two most bearish-leaning lenses said would flip them from cautious to outright Bearish: it broke the $31 shelf on real volume, and it did so despite a mildly favorable FDA headline, which both of those lenses read as the market discounting execution risk harder than it's crediting regulatory news. At the same time, the quarter's one clean new data point — a raised revenue and EBITDA guide — is the first hint that gross margin might be stabilizing near 65% rather than continuing to erode, which is the exact evidence the four Neutral lenses say they need before moving off the sideline in either direction. With price now sitting essentially on the more recent analyst consensus reading (~$28, StockAnalysis.com) rather than below it as last week, and the August 10 Q2 print now the confirmed single catalyst everyone is still waiting on, the panel's majority stays parked at WAIT — just with a harder edge on the bear side than seven days ago.

Key levels

The old $31-32 shelf is broken and has flipped to overhead resistance, converging with the failed-rally highs at $35-36 from the last two weeks into a single near-term resistance band (31-36) that price would need to reclaim on volume to negate this week's bearish read. The prior R1 zone (38-41) and the deeper R2 (50) both hold, unchanged and untested — the rally this cycle only reached $35.85. On the downside, the former $27-29 shelf that used to be labeled deeper support is now the live battleground: current price ($28.09) sits inside it, making $27 the immediate line — a close and hold below it opens the $22 zone, with the $19 area still marking the top of the broader bear-case range from the prior basing structure. The analyst consensus target has drifted down to roughly USD 21-28-40 (StockAnalysis.com, more current read), now sitting almost exactly on top of the stock rather than below it as it was last week.

What legendary investors think

We ran Hims & Hers past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the August 10 print show the raised FY26 guidance translating into gross margin actually stabilizing near 65% — validating the "dented, not broken" reading — or does it confirm that the market's rejection of a genuinely positive FDA headline this week was smart money front-running a deteriorating quarter?

The numbers

Metric	Value
Price / Market cap	USD 28.09 / ~$6.9B
P/E (TTM / fwd)	n/a (net loss, TTM) / ~33x–70x (fwd, conflicting sources this week)
ROE	n/a (not reported)
Revenue growth	+4% YoY (Q1'26); Q2 guide +25-28% YoY ($680-700M)
Gross margin	65% (unchanged since Q1)
Net income (Q1)	−USD 92M
Free cash flow	+USD 53M (positive)
Subscribers	2.6M
Short interest	~42.8% of float (near record)

Figures as of Q1 2026 results, cross-referenced against the July 18, 2026 analysis and updated with July 22-25, 2026 sources (GuruFocus, TIKR, Simply Wall St, StockAnalysis.com). Forward P/E is genuinely conflicted this week — roughly 33x per last week's baseline versus roughly 70x per a widened 2026 EPS-loss estimate — and shouldn't be anchored on either way until the August print resets the earnings base. Next print: Q2 2026 earnings, after market close, Monday, August 10, 2026.

The bottom line

What would move this off WAIT: a close and hold below $27 on volume would confirm the Forensic Skeptic and Macro Opportunist's read that this week's breakdown is the start of a genuine repricing toward the $22-19 bear-case zone rather than a one-week overreaction, while a reclaim of the new $31-36 resistance band on real volume would restore the prior base structure and bring the Macro Opportunist back to neutral. The harder catalyst is still the August 10 print: gross margin holding near 65% alongside the raised guidance actually showing up in the numbers would give the four Neutral lenses the evidence they've been waiting on to move off the sideline, most likely toward the Moat Compounder's "dented, not broken" read; a miss, a fresh margin leg down, or any irregularity surfacing during the CAO handoff would instead confirm the Forensic Skeptic's now-High-conviction Bearish case. Until then, 42.8% short interest keeps two-way volatility elevated, and a governance backdrop — a CFO selling into an FDA catalyst, a CAO departing weeks before earnings — adds a layer of caution that wasn't part of last week's picture.

The panel's take

Verdict: SELL · Conviction: HIGH · Last price: USD 27.77 (as of 2026-08-01) · Changed from WAIT

What changed since 2026-07-25:

• Price: USD 28.09 → 27.77 (-1.14%)
• Panel: 0 of 6 → 0 of 6 now Bullish — composition also changed: added The Asymmetric Bargainer; removed The Macro Opportunist
• Trigger: Sustained GAAP profitability with free cash flow covering interest >2x, revenue re-acceleration above 10-20% YoY, meaningful debt reduction, and insider buying. Alternatively, a price collapse to the $10–15 range where asset-value support begins to emerge — but business quality must show genuine repair, not just a cheaper price.
• Verdict: WAIT → SELL

The prior panel (July 2026) issued a WAIT at $28.09, with six archetypes seeing enough uncertainty to stay on the sidelines. This time, the addition of The Asymmetric Bargainer sharpened the frame: the downside math is now so lopsided — a potential 60–80% loss versus a capped 30% gain — that even waiting at $28 is costly. Meanwhile, fundamentals have continued to erode with another quarter of near-zero growth and widening GAAP losses, and no archetype stepped forward to defend the business. The verdict flipped from WAIT to SELL not because the price moved meaningfully, but because the passage of time revealed that the deterioration is structural, not transitional.

The split is not ambiguous: 8 of 9 voices identify fundamental business deterioration — collapsed growth from 73% CAGR to 3.8%, negative GAAP earnings, a levered balance sheet with zero interest coverage, and no durable moat. The lone WAIT (technical-scout) is a timing call waiting for base resolution, not a defense of the business. This is SELL, not WAIT or HOLD, because the objection is to the company itself — a deteriorating business at an unsupported price with no margin of safety — not merely a case of buying at an unattractive price.

Key levels

What legendary investors think

We ran Hims & Hers Health, Inc. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Can HIMS produce sustained GAAP profitability and revenue re-acceleration above 10% before its levered balance sheet forces a dilutive capital raise or debt restructuring?

The numbers

Metric	Value
Price / Market cap	USD 27.77 / n/a
P/E (TTM / fwd)	57.14x / 58.82x
ROE	-2.66%
Operating margin	n/a
Dividend yield	n/a
Debt / equity	2.54x
Free cash flow	USD 174.31M

Figures as of 2026-08-01; sourced from Yahoo Finance and TipRanks. Operating margin, dividend yield, and market cap were not returned by the source query and are marked n/a. The analyst consensus average (~USD 30.70) is as referenced by the panel; a low–high range was not available from the source data.

The bottom line

Watch HIMS's Q2 2026 earnings for two specific numbers: revenue growth turning negative would confirm the growth story is fully dead, and any mention of debt-covenant compliance or a dilutive equity offering would signal the balance-sheet risk is materializing. Conversely, a genuine GAAP-profit surprise with free cash flow covering interest expense by at least 2x — combined with insider buying rather than selling — would be the earliest signal that a turnaround is credible. On the price side, a collapse below $10–15 would bring the stock closer to The Intrinsic-Value Modeler's bear-case value of ~$10 and The Forensic Skeptic's tangible-book anchor near $6, at which point the debate would shift from "is this overvalued" to "is the business genuinely salvageable." Until one of these conditions materializes, the data continues to favor downside over upside.

The panel's take

Verdict: SELL · Conviction: HIGH · Last price: 31.59

What changed since 2026-08-01:

• Price: 27.77 → 31.59 (+13.76%)
• Panel: 0 of 6 → 1 of 6 now Bullish — composition also changed: added The Quality Rationalist; removed The Moat Compounder
• Trigger: A definitive SEC filing confirming an exclusive, multi-year Novo Nordisk partnership with favorable revenue-sharing terms (>40% to HIMS, 3+ year commitment), AND a subsequent quarterly report showing positive GAAP net income, subscriber re-acceleration (>20% YoY), and operating margins returning to positive territory — together, these would re-open the BUY case. Alternatively, a monthly close above $37.85 (50% Fib) with monthly MACD turning positive would signal the technical all-clear, but only if accompanied by fundamental improvement.
• Verdict: SELL (unchanged)

The prior panel was unanimously bearish at $27.77. Since then, the stock rallied 13.8% to $31.59, but the business fundamentals deteriorated further: negative TTM earnings materialized, operating margins swung deeper into the red, and Novo Nordisk launched its own direct Wegovy subscription plan in July, directly undercutting the one bullish catalyst. The week's MACD crossover added a lone GARP bull to the panel, but the dominant voices see a company whose balance sheet and competitive position have worsened even as the price rose, reinforcing the SELL at higher conviction rather than weakening it.

This is a BUSINESS-dominant split, not a PRICE/TIMING split. The fundamental-scout, The Intrinsic-Value Modeler, The Forensic Skeptic, and The Disruptive-Innovation Seeker all identify structural business deterioration: no moat, decelerating growth, negative TTM earnings, surging leverage (D/E 0.02→2.52), negative interest coverage, and Novo's direct subscription plan undercutting the sole bullish catalyst. The lone bull (The GARP Operator) leans on a weekly MACD crossover and "out-of-favor" sentiment, but that is a price/timing argument against a wall of business-level objections. Technical-scout is WAIT on timing, The Quality Rationalist and The Asymmetric Bargainer are neutral on price, but the dominant voices articulate a deteriorating company, not just a stretched valuation. The net verdict is strongly against at today's price: SELL.

Key levels

What legendary investors think

We ran Hims & Hers Health, Inc. past a panel of 6 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is HIMS's GLP-1 distribution thesis a durable competitive advantage that justifies 40x forward earnings and a leveraged balance sheet, or is it a temporary regulatory window that Novo Nordisk's direct subscription plan is already closing?

The bottom line

• Trigger to confirm the breakdown: A Q2 2026 earnings report showing another quarter of negative operating margins and subscriber growth below 15% YoY would validate the structural-deterioration thesis and likely break the 20-month EMA ($31.05).
• Risk to monitor: Novo Nordisk's direct Wegovy subscription plan gaining measurable traction: any disclosure of subscriber uptake that bypasses HIMS entirely would collapse the GLP-1 distribution narrative.
• Next catalyst: A definitive SEC filing with Novo Nordisk partnership terms: if the revenue share is below 40% or the commitment is under 3 years, the bull case ($44+) is invalidated; if above 40% with 3+ year exclusivity, the bear case weakens materially.
• Further out: Positive monthly MACD (histogram ≥ 0) combined with a monthly close above $37.85 (50% Fibonacci retracement) would signal the technical all-clear, but only alongside GAAP profitability, which remains unproven.